Non-small Cell Lung Cancer: Seven-Market Drug Forecast and Market Analysis

Non-small Cell Lung Cancer: Seven-Market Drug Forecast and Market Analysis

Summary

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 7MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for non-small cell lung cancer (NSCLC).

These sales forecasts leverage data on pharmaceutical sales and drug availability from GlobalData’s World Markets Healthcare (WMH) and POLI Price Intelligence databases.

Key Highlights

• Report deliverables include a Pdf and Excel-based forecast model.
• Forecasts includes the seven major markets (7MM: US, France, Germany, Italy, Spain, the UK, and Japan) and cover 2022-2032.
• GlobalData valued the NSCLC market in the 7MM at $24.1 billion in the 2022 base year and expects the market to reach $56.5 billion by 2032 at a compound annual growth rate (CAGR) of 8.9%.
• This growth is driven by the market entry of more than 40 pipeline agents across patient segments and the active label expansion of marketed agents to address the earlier stage of the disease.
• The second- and third-line settings are expected to see greater growth than the neo/adjuvant, consolidation, and first-line settings, due to the introduction of pipeline agents with differentiated modalities replacing the use of the more economical chemotherapy.
• The growth momentum towards the end of the forecast period is partially offset by the loss of exclusivity of the mainstream PD-1 inhibitors and high-profile kinase inhibitors, such as Tagrisso and Alecensa.

This report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 7MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for NSCLC. These sales forecasts leverage data on pharmaceutical sales and drug availability from GlobalData’s World Markets Healthcare (WMH) and POLI Price Intelligence databases.

The incidence of NSCLC is growing steadily across the 7MM. Global Data expects the number of diagnosed incident cases of Non-small Cell Lung Cancer (NSCLC) to be 514,561 in 2022, rising to a total of 564,314 by 2032 in the seven major markets.

Common NSCLC market drivers across the 7MM include -

• Immune checkpoint inhibitors, along with the development of combination therapies and targeted therapies, are driving market growth in 7MM.
• The US market is expected to maintain its dominance because of the rising prevalence of NSCLC, advanced screening, and new drugs approval such as new ADC and ICI products during the forecast period.
• A total of 42 novel drugs are expected to enter 7MM during the forecast period, and those drugs will drive total NSCLC market sales. In addition, currently marketed agents are expected to gain label expansions for use in earlier settings.
• Precision medicine is advanced by biomarker-driven therapies like AstraZeneca’s Tagrisso for EGFR mutations and Roche’s Alecensa for ALK-positive NSCLC. This trend is driving market growth by improving access to innovative treatments.

Common barriers to market growth experienced across the 7MM include -

• The high cost of new NSCLC treatment makes them harder for patients to get, even though reimbursement policies are usually good.
• The entry of biosimilars and generic erosion of marketed products will cause the market to become more fragmented, putting pressure on prices and profits.
• Managing the adverse effects of combination therapies is challenging, impacting patient adherence and overall treatment outcomes.
• This report covers the seven major markets (7MM: US, France, Germany, Italy, Spain, the UK, and Japan).
• The report provides an overview of the current treatment options, pipeline products in development, as well as current and future R&D trends.
• Key topics covered include a strategic competitive assessment of current and future drugs, unmet needs, KOL insights, and implications for the NSCLC market.
• The base year of the sales forecast model is 2022, and the forecast period is 2022-2032.

Scope

• Overview of NSCLC, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized NSCLC therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2022 to 2032.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the NSCLC therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for NSCLC treatment. The most promising candidates in Phase III and Phase IIb development are profiled.
• Analysis of the current and future market competition in the global NSCLC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global NSCLC therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global NSCLC therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Please note:this is delivered as a zip file.